Brad Wilson ☑️’s Post

🎉 We’re thrilled to announce a new partnership with SanMed! Together, we'll bring top-tier cardiovascular education to China, empowering healthcare professionals and enhancing patient care. 🌍KEY DETAILS OF THE PARTNERSHIP: • Content Translation and Distribution: SanMed will translate and promote Radcliffe’s comprehensive educational content, including articles and videos, tailored to the needs of Chinese physicians. • Exclusive Rights: SanMed will have exclusive rights to distribute Radcliffe’s content in China, ensuring tailored and impactful delivery. • Integration with Local Societies: SanMed maintains close collaborations with leading Chinese medical societies, fostering a robust academic community. o China Anti-Cancer Association (CACA) o Chinese Society of Clinical Oncology (CSCO) o Chinese Medical Association (CMA) 🌍 OBJECTIVES AND EXPECTATIONS: • Enhance Clinical Care and Patient Outcomes: By equipping healthcare providers with the latest and best in cardiovascular science, we aim to directly improve patient care practices and outcomes. • Expand Global Reach: This initiative will extend our influence and capabilities to a vital segment of the global healthcare community. Together, we will bring Radcliffe Group’s expert content to thousands of Chinese healthcare professionals, supporting superior patient outcomes and extending our global impact. Read more at: https://lnkd.in/e8MDUNVg #MedicalEducation #HeartHealth #GlobalPartnership #RadcliffeGroup #SanMed #HealthcareInnovation

🎉 We’re thrilled to announce a new partnership with SanMed! Together, we'll bring top-tier cardiovascular education to China, empowering healthcare professionals and enhancing patient care. 🌍KEY DETAILS OF THE PARTNERSHIP: • Content Translation and Distribution: SanMed will translate and promote Radcliffe’s comprehensive educational content, including articles and videos, tailored to the needs of Chinese physicians. • Exclusive Rights: SanMed will have exclusive rights to distribute Radcliffe’s content in China, ensuring tailored and impactful delivery. • Integration with Local Societies: SanMed maintains close collaborations with leading Chinese medical societies, fostering a robust academic community. o China Anti-Cancer Association (CACA) o Chinese Society of Clinical Oncology (CSCO) o Chinese Medical Association (CMA) 🌍 OBJECTIVES AND EXPECTATIONS: • Enhance Clinical Care and Patient Outcomes: By equipping healthcare providers with the latest and best in cardiovascular science, we aim to directly improve patient care practices and outcomes. • Expand Global Reach: This initiative will extend our influence and capabilities to a vital segment of the global healthcare community. Together, we will bring Radcliffe Group’s expert content to thousands of Chinese healthcare professionals, supporting superior patient outcomes and extending our global impact. Read more at: https://lnkd.in/e8MDUNVg #MedicalEducation #HeartHealth #GlobalPartnership #RadcliffeGroup #SanMed #HealthcareInnovation

🎉 We’re thrilled to announce a new partnership with SanMed! Together, we'll bring top-tier cardiovascular education to China, empowering healthcare professionals and enhancing patient care. 🌍KEY DETAILS OF THE PARTNERSHIP: • Content Translation and Distribution: SanMed will translate and promote Radcliffe’s comprehensive educational content, including articles and videos, tailored to the needs of Chinese physicians. • Exclusive Rights: SanMed will have exclusive rights to distribute Radcliffe’s content in China, ensuring tailored and impactful delivery. • Integration with Local Societies: SanMed maintains close collaborations with leading Chinese medical societies, fostering a robust academic community. o China Anti-Cancer Association (CACA) o Chinese Society of Clinical Oncology (CSCO) o Chinese Medical Association (CMA) 🌍 OBJECTIVES AND EXPECTATIONS: • Enhance Clinical Care and Patient Outcomes: By equipping healthcare providers with the latest and best in cardiovascular science, we aim to directly improve patient care practices and outcomes. • Expand Global Reach: This initiative will extend our influence and capabilities to a vital segment of the global healthcare community. Together, we will bring Radcliffe Group’s expert content to thousands of Chinese healthcare professionals, supporting superior patient outcomes and extending our global impact. Read more at: https://lnkd.in/e8MDUNVg #MedicalEducation #HeartHealth #GlobalPartnership #RadcliffeGroup #SanMed #HealthcareInnovation

🎉 We’re thrilled to announce a new partnership with SanMed! Together, we'll bring top-tier cardiovascular education to China, empowering healthcare professionals and enhancing patient care. 🌍KEY DETAILS OF THE PARTNERSHIP: • Content Translation and Distribution: SanMed will translate and promote Radcliffe’s comprehensive educational content, including articles and videos, tailored to the needs of Chinese physicians. • Exclusive Rights: SanMed will have exclusive rights to distribute Radcliffe’s content in China, ensuring tailored and impactful delivery. • Integration with Local Societies: SanMed maintains close collaborations with leading Chinese medical societies, fostering a robust academic community. o China Anti-Cancer Association (CACA) o Chinese Society of Clinical Oncology (CSCO) o Chinese Medical Association (CMA) 🌍 OBJECTIVES AND EXPECTATIONS: • Enhance Clinical Care and Patient Outcomes: By equipping healthcare providers with the latest and best in cardiovascular science, we aim to directly improve patient care practices and outcomes. • Expand Global Reach: This initiative will extend our influence and capabilities to a vital segment of the global healthcare community. Together, we will bring Radcliffe Group’s expert content to thousands of Chinese healthcare professionals, supporting superior patient outcomes and extending our global impact. Read more at: https://lnkd.in/e8MDUNVg #MedicalEducation #HeartHealth #GlobalPartnership #RadcliffeGroup #SanMed #HealthcareInnovation

How can healthcare be transformed by innovative assessment and evaluation? ACER researchers Jacob Pearce, Kristy Osborne (Vernon), Neville Chiavaroli and Clare Ozolins added their expertise to the premier #Ottawa2024 conference recently. Read the highlights of their presentations and workshops - aimed at improving and enhancing the assessment of clinical competence - in this new Discover article. https://brnw.ch/21wI6Ao

Have you ever wondered how the unique cultural diversity of Latin America influences clinical trials and medical device innovation? With its rich tapestry of populations, this region offers unparalleled opportunities for robust and inclusive research. The extensive genetic variability across Latin American countries provides an exceptional environment for trial diversity, ensuring that new medical devices cater to a wide range of human conditions. By conducting trials here, companies can gather data that truly reflects the global population. Moreover, the increasing investment in healthcare infrastructure and regulatory support is accelerating trial timelines, presenting a win-win scenario for researchers and patients alike. As we continue to explore these dynamic landscapes, how do you foresee the role of Latin America evolving in the global medical device arena? Let's keep pushing boundaries together! #ClinicalTrials #MedicalDeviceInnovation 🌎🔬

BostonGene had the honor to welcome a delegation from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung) in our laboratory. A big thank you to the German Consulate Boston and the amazing LAURA UDDEN for organizing. Briefly, the Directorate-General 2 of the Federal Ministry is entitled "European and International Cooperation in Education and Research" – and responsible for the governance and development of Germany's international cooperation in education and research. The Division 213 (our visitors) is coordinating collaborations with North- and South America. Undersecretary Vivien Baganz, who leads the Division 213, and Jill Theuring from her division, alongside our Consul General Dr. Sonja Kreibich and the senior science and economic advisor Yannic Arnold, joined our VP of Product Development Alexander Bagaev and Director of Immunology and Immunoprofiling Michael Goldberg for a tour through the laboratory and a focused discussion. Topics included: - Technology transfer and translation from development to clinical practice - Health data utilization and data- and AI-based diagnostics - Consent management including use for research, and recall when new therapies become available - Abstraction of electronic patient records to streamline physician time and much more... It was a pleasure and honor meeting you and we hope our perspectives were valuable. German consulate Boston: https://lnkd.in/ec2GiDch Organization of the BMBF: https://lnkd.in/esvCAQEW BostonGene Bundesministerium für Bildung und Forschung #healthdata #Dataforhealth #datautilization #diagnostics #biomarker #digitalization #GDNG #precisionmedicine #precisiononcology #policymakers #medicaldata

60 years after its presentation, the Declaration of Helsinki that presents Ethical Principles for Medical Research Involving Human Participants has received its 10th update which has been published last week. It regulates the involvement of human subjects in medical research, the consideration how results may benefit or risk not only these subjects but entire communities, consent of subjects etc. Evidence has shown how medical - and kindred - research has not served the human population on equal footing by having often excluded half of the population since male participants are not influenced by short- and long-term hormonal cycles with researchers still assuming that results were applicable equally to the other half. Similarly, research is often guided by economical, profit-driven goals, with important diseases that affect poorer regions more than affluent ones being underattended. The new declaration repairs some of these and other issues, but certainly not all, it appears: https://lnkd.in/eTYeDYs5 . As I'm preparing my contributions to next week's International Inter- and Transdisciplinary Conference in which my focus is on the epistemic injustice suffered by neurodiverse communities in cognitive neuroscientific research and the forms of epistemic resistance they can perform, I've checked the new declaration against this background. ( https://lnkd.in/ej2PD3bs ) From that perspective, the change in reference to research 'participants' instead of 'subjects' is significant and this text goes some way in creating balance: "Meaningful engagement with potential and enrolled participants and their communities should occur before, during, and following medical research. Researchers should enable potential and enrolled participants and their communities to share their priorities and values; to participate in research design, implementation, and other relevant activities; and to engage in understanding and disseminating results." Nonetheless, the research initiative and agenda still remains at the part of the researchers without a mechanism of readjusting these. Another improvement pertains to 'Individual, Group, and Community Vulnerability'. The text now discourages exclusion of vulnerable groups as that may harm them more than being included in research, since researchers often excluded them as a way of avoiding risks: "When such individuals, groups, and communities have distinctive health needs, their exclusion from medical research can potentially perpetuate or exacerbate their disparities. Therefore, the harms of exclusion must be considered and weighed against the harms of inclusion. In order to be fairly and responsibly included in research, they should receive specifically considered support and protections." Notwithstanding improvements, research-dependent health equity is still not created... #transdisciplinaryresearch #itd2024 #diversityequityinclusion #centraldiversityoffice

Exciting Milestone: $18.8 Million Boost for the National One Stop Shop for Clinical Trials and Health Research I am immensely proud to share a significant achievement that's been years in the making. Thanks to the relentless dedication and hard work of the Clinical Trials Project Reference Group, now called the Inter-Governmental Policy Reform Group (IGPRG), $18.8 million has been secured to advance the National One Stop Shop for clinical trials and health research. This initiative, a testament to the transformative power of collaboration, represents a significant step forward for health and medical research in Australia. The journey to this point has been filled with persistent efforts, deep and broad consultations, detailed negotiations, and an unwavering commitment to listening and understanding the needs within our sector (too many to mention but for one example the R&D Taskforce). A commitment to remain steadfast, undeterred by challenges, and focused on strategic objectives has paid off, and it's time to move forward at full speed. For more details on this groundbreaking initiative, visit [Transforming Health and Medical Research in Australia](https://lnkd.in/gbENUpic).

Check out Xtalks' new article in collaboration with Stacy Weil, where they discuss the importance of incorporating #DEI strategies into clinical research and why early planning is imperative. https://lnkd.in/e6cn-5Ss #Diversity #Equity #Inclusion #ClinicalResearch